Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
|
|
Reprints, Electronic Licenses, Distribution Rights and Academic Use
Print and electronic reprints from Windhover Information are available for purchase to complement your marketing efforts. Windhover’s expert, in-depth editorial content provides an objective perspective regarding your products, services and company to investors, shareholders, potential partners and others.
Ideal for use with…
- Trade Shows, Conferences and Seminars
- Customer Communications
- Public Relations
- Media Kits
- Education and Training Programs
- Web Content
- Investor Relations
- E-marketing
Product Offerings
- Print Reprints
Optional customization available. - Online Article Licensing
Permission to post PDF of article for online use.
Rates available for 6-months, 12-months and unlimited use. - E-Prints – Permission to email PDF of article
Rates based on number of emails sent. - Intranet Article Licensing
Unlimited use available for internal client use only. - Academic Rates Available
To obtain a price quote and/or additional product information - please contact:
Pat Cardone
Phone:
(203) 838-4401 x124
Email:
p.cardone@elsevier.com
|
|
 |
|
 |
|
|
| |
 |
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications. . . [MORE] (IN VIVO)
Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. . . [MORE] (Start-Up)
The Future of Drug-Eluting Stents Part II: Biodegradable Platforms
The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. . . [MORE] (Medtech Insight)
Health Reform in the Balance: What It Means for Biopharma
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|
